First Header Logo Second Header Logo

Connection

Thomas Wierzba to Enterotoxigenic Escherichia coli

This is a "connection" page, showing publications Thomas Wierzba has written about Enterotoxigenic Escherichia coli.
  1. Barry E, Cassels F, Riddle M, Walker R, Wierzba T. Vaccines Against Shigella and Enterotoxigenic Escherichia coli: A summary of the 2018 VASE Conference. Vaccine. 2019 08 07; 37(34):4768-4774.
    View in: PubMed
    Score: 0.680
  2. Wierzba TF, Bourgis A. Defining cases of severe pediatric diarrhea for an efficacy trial of an enterotoxigenic Escherichia coli (ETEC) vaccine: Report on an international workshop, Washington DC, March 2016. Vaccine. 2017 01 23; 35(4):503-507.
    View in: PubMed
    Score: 0.567
  3. Qadri F, Akhtar M, Bhuiyan TR, Chowdhury MI, Ahmed T, Rafique TA, Khan A, Rahman SIA, Khanam F, Lundgren A, Wiklund G, Kaim J, Löfstrand M, Carlin N, Bourgeois AL, Maier N, Fix A, Wierzba T, Walker RI, Svennerholm AM. Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2020 02; 20(2):208-219.
    View in: PubMed
    Score: 0.173
  4. Wierzba TF. Implications and measurement of herd protection (indirect effects) for enteric vaccine development. Vaccine. 2019 08 07; 37(34):4775-4777.
    View in: PubMed
    Score: 0.170
  5. Akhtar M, Chowdhury MI, Bhuiyan TR, Kaim J, Ahmed T, Rafique TA, Khan A, Rahman SIA, Khanam F, Begum YA, Sharif MZ, Islam LN, Carlin N, Maier N, Fix A, Wierzba TF, Walker RI, Bourgeois AL, Svennerholm AM, Qadri F, Lundgren A. Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses. Vaccine. 2019 09 03; 37(37):5645-5656.
    View in: PubMed
    Score: 0.162
  6. Bourgeois AL, Wierzba TF, Walker RI. Status of vaccine research and development for enterotoxigenic Escherichia coli. Vaccine. 2016 06 03; 34(26):2880-2886.
    View in: PubMed
    Score: 0.134
  7. Desai SN, Sahastrabuddhe S, Ochiai RL, Wierzba TF. Enteric vaccines for resource-limited countries: current status and future prospects. Pediatr Ann. 2011 Jul; 40(7):351-7.
    View in: PubMed
    Score: 0.097
  8. Anderson JD, Bagamian KH, Muhib F, Amaya MP, Laytner LA, Wierzba T, Rheingans R. Burden of enterotoxigenic Escherichia coli and shigella non-fatal diarrhoeal infections in 79 low-income and lower middle-income countries: a modelling analysis. Lancet Glob Health. 2019 03; 7(3):e321-e330.
    View in: PubMed
    Score: 0.041
  9. Walker RI, Wierzba TF, Mani S, Bourgeois AL. Vaccines against Shigella and enterotoxigenic Escherichia coli: A summary of the 2016 VASE Conference. Vaccine. 2017 12 14; 35(49 Pt A):6775-6782.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.